|  |  |
| --- | --- |
| **Drug / Compound “CV”** | **Current information** |
| **Drug name, alternative name** |  |
| Drug class |  |
| British National Formulary code (if applicable) |  |
|  |  |
| **Safety record** |  |
| Toxicology studies |  |
| Tested in humans |  |
| Side effects |  |
| Possible off target effects |  |
| Contraindications |  |
|  |  |
| Efficacy in models |  |
| Mode of delivery |  |
| Dose |  |
|  |  |
| **Owner/owners** |  |
| IP landscape/patent duration |  |
| Delivery mechanism |  |
| Licence status |  |
|  |  |
| Target molecular pathway |  |
| Selectivity |  |
| Protective/restorative |  |
| Tested/Used for which conditions |  |
| PK, PD, ADME |  |
| CNS penetration |  |
|  |  |
| **Steps for clinical translation** |  |
| Further preclinical work? |  |
| Drugs for comparison? |  |
| Regulatory concerns |  |